BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12854905)

  • 1. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.
    Wang ES; O'Connor O; She Y; Zelenetz AD; Sirotnak FM; Moore MA
    Leuk Lymphoma; 2003 Jun; 44(6):1027-35. PubMed ID: 12854905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
    Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
    Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
    Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
    Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.
    Kang MH; Harutyunyan N; Hall CP; Papa RA; Lock RB
    Br J Haematol; 2009 May; 145(3):389-93. PubMed ID: 19298590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
    Krug LM; Azzoli CG; Kris MG; Miller VA; Khokhar NZ; Tong W; Ginsberg MS; Venkatraman E; Tyson L; Pizzo B; Baez V; Ng KK; Sirotnak FM
    Clin Cancer Res; 2003 Jun; 9(6):2072-8. PubMed ID: 12796370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.
    Khokhar NZ; She Y; Rusch VW; Sirotnak FM
    Clin Cancer Res; 2001 Oct; 7(10):3199-205. PubMed ID: 11595715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions.
    McPherson JP; Vrontikis A; Sedillo C; Halwani AS; Gilreath JA
    Pharmacotherapy; 2016 Feb; 36(2):e8-e11. PubMed ID: 26809959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the sensitivity of head and neck cell lines to methotrexate (MTX) and the analog 10-ethyl, 10-deazaaminopterin (10-EdAM).
    Brown DH; Braakhuis BJ; Van Dongen GA; Snow GB
    Otolaryngol Head Neck Surg; 1990 Jan; 102(1):20-5. PubMed ID: 2106113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
    Sirotnak FM; Wendel HG; Bornmann WG; Tong WP; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Sep; 6(9):3705-12. PubMed ID: 10999764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate.
    van der Laan BF; Jansen G; Kathmann GA; Westerhof GR; Schornagel JH; Hordijk GJ
    Int J Cancer; 1992 Jul; 51(6):909-14. PubMed ID: 1639538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro.
    Samuels LL; Moccio DM; Sirotnak FM
    Cancer Res; 1985 Apr; 45(4):1488-95. PubMed ID: 3978616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts.
    Brown DH; Braakhuis BJ; van Dongen GA; van Walsum M; Bagnay M; Snow GB
    Anticancer Res; 1989; 9(6):1549-52. PubMed ID: 2627109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
    Hui J; Przespo E; Elefante A
    J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
    Diddens H; Niethammer D; Jackson RC
    Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pralatrexate: basic understanding and clinical development.
    Zain J; O'Connor O
    Expert Opin Pharmacother; 2010 Jul; 11(10):1705-14. PubMed ID: 20509772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity.
    Rumberger BG; Schmid FA; Otter GM; Sirotnak FM
    Cancer Commun; 1990; 2(9):305-10. PubMed ID: 2206778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.